litlas
Log inCreate account

Gary Remington

Active 1979–2025

137
Papers
18,303
Citations
81
h-index
135
i10-index

Citations

Citations per year for Gary Remington1979: 6 citations1980: 5 citations1981: 8 citations1982: 7 citations1983: 3 citations1984: 4 citations1985: 3 citations1986: 2 citations1987: 5 citations1988: 3 citations1989: 3 citations1990: 2 citations1991: 3 citations1992: 3 citations1993: 4 citations1994: 7 citations1995: 20 citations1996: 13 citations1997: 32 citations1998: 27 citations1999: 63 citations2000: 41 citations2001: 58 citations2002: 66 citations2003: 78 citations2004: 95 citations2005: 100 citations2006: 120 citations2007: 108 citations2008: 126 citations2009: 103 citations2010: 98 citations2011: 119 citations2012: 126 citations2013: 129 citations2014: 139 citations2015: 135 citations2016: 166 citations2017: 174 citations2018: 137 citations2019: 512 citations2020: 507 citations2021: 478 citations2022: 404 citations2023: 301 citations2024: 508 citations2025: 211 citations2026: 9 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,563 citing papers, 23.4% of this breakdownUnited Kingdom: 700 citing papers, 10.5% of this breakdownCanada: 598 citing papers, 9% of this breakdownGermany: 409 citing papers, 6.1% of this breakdownItaly: 309 citing papers, 4.6% of this breakdownChina: 282 citing papers, 4.2% of this breakdownAustralia: 277 citing papers, 4.2% of this breakdownSpain: 209 citing papers, 3.1% of this breakdownNetherlands: 174 citing papers, 2.6% of this breakdownJapan: 171 citing papers, 2.6% of this breakdownSwitzerland: 165 citing papers, 2.5% of this breakdownFrance: 163 citing papers, 2.4% of this breakdown
0%23.4%Other 24.8%

Institutions

Fields

  • Medicine58.2%
  • Neuroscience27.3%
  • Biochemistry, Genetics and Molecular Biology6.7%
  • Psychology4.5%
  • Computer Science0.7%
  • Pharmacology, Toxicology and Pharmaceutics0.6%
  • Other2%

Topics

  • Schizophrenia research and treatment18.3%
  • Tryptophan and brain disorders5.6%
  • Neurotransmitter Receptor Influence on Behavior5%
  • Bipolar Disorder and Treatment4%
  • Functional Brain Connectivity Studies3.4%
  • Mental Health and Psychiatry3.4%
  • Other60.3%

Coauthors

All papers

Open in search
  1. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology

    Authors: Oliver Howes, Robert A. McCutcheon, Ofer Agid, Andrea de Bartolomeis, Nico J.M. van Beveren, Michael L. Birnbaum, Michael Bloomfield, Rodrigo A. Bressan, Robert W. Buchanan, William T. Carpenter, David Castle, Leslie Citrome, Zafiris J. Daskalakis, Michael Davidson, Richard Drake, Serdar Dursun, Bjørn H. Ebdrup, Hélio Elkis, Peter Falkai, W. Wolfgang Fleischacker, Ary Gadelha, Fiona Gaughran, Birte Glenthøj, Ariel Graff‐Guerrero, Jorge Hallak, William G. Honer, James L. Kennedy, Bruce J. Kinon, Stephen M. Lawrie, Jimmy Lee, F. Markus Leweke, James H. MacCabe, Carolyn McNabb, Herbert Y. Meltzer, Hans‐Jürgen Möller, Shinchiro Nakajima, Christos Pantelis, Tiago Reis Marques, Gary Remington, Susan L. Rossell, Bruce R. Russell, Cynthia Siu, Takefumi Suzuki, Iris E. Sommer, David Taylor, Neil Thomas, Alp Üçok, Daniel Umbricht, James Walters, John M. Kane, Christoph U. Correll - American Journal of Psychiatry 2016 cited by 1,106

  2. Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis

    Authors: Eric Plitman, Yusuke Iwata, Fernando Caravaggio, Shinichiro Nakajima, Jun Ku Chung, Philip Gerretsen, Julia Kim, Hiroyoshi Takeuchi, M. Mallar Chakravarty, Gary Remington, Ariel Graff‐Guerrero - Schizophrenia Bulletin 2017 cited by 244

  3. Guidelines for the Pharmacotherapy of Schizophrenia in Adults

    Authors: Gary Remington, Donald Addington, William G. Honer, Zahinoor Ismail, Thomas J. Raedler, Michael D. Teehan - The Canadian Journal of Psychiatry 2017 cited by 322

  4. Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia

    Authors: Shitij Kapur, Robert B. Zipursky, Corey Jones, Gary Remington, Sylvain Houle - American Journal of Psychiatry 2000 cited by 1,083

  5. Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health

    Authors: Nicolette Stogios, Alexander Gdanski, Philip Gerretsen, Araba Chintoh, Ariel Graff‐Guerrero, Tarek K. Rajji, Gary Remington, Margaret Hahn, Sri Mahavir Agarwal - Schizophrenia 2021 cited by 93

  6. Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series

    Authors: Femin Prasad, Riddhita De, Vittal Korann, Araba Chintoh, Gary Remington, Bjørn H. Ebdrup, Dan Siskind, Filip K. Knop, Tina Vilsbøll, Anders Fink‐Jensen, Margaret Hahn, Sri Mahavir Agarwal - Therapeutic Advances in Psychopharmacology 2023 cited by 86

  7. Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia

    Authors: Nicole E. MacKenzie, Chantel Kowalchuk, Sri Mahavir Agarwal, Kenya A. Costa-Dookhan, Fernando Caravaggio, Philip Gerretsen, Araba Chintoh, Gary Remington, Valerie H. Taylor, Daniel J. Müller, Ariel Graff‐Guerrero, Margaret Hahn - Frontiers in Psychiatry 2018 cited by 207

  8. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia

    Authors: Hiroyoshi Takeuchi, Cynthia Siu, Gary Remington, Gagan Fervaha, Robert B. Zipursky, George Foussias, Ofer Agid - Neuropsychopharmacology 2018 cited by 201

  9. Clozapine Optimization: A Delphi Consensus Guideline From the Treatment Response and Resistance in Psychosis Working Group

    Authors: Elias Wagner, Dan Siskind, Peter Falkai, Oliver Howes, Christoph U. Correll, Jimmy Lee, William G. Honer, John M. Kane, Emilio Fernández-Egea, Thomas R. E. Barnes, Alkomiet Hasan, TRRIP Working Group, Ofer Agid, Celso Arango, Lone Baandrup, Thomas R. E. Barnes, Andrea de Bartolomeis, Nico J.M. van Beveren, Michael L. Birnbaum, István Bitter, Alain Breier, Robert W. Buchanan, William T. Carpenter, David Castle, Eric Chen, Leslie Citrome, David Cotter, Christoph U. Correll, Benedicto Crespo‐Facorro, Michael Davidson, Richard Drake, Sonia Dollfus, Serdar Dursun, Bjørn H. Ebdrup, Robin Emsley, Emilio Fernández-Egea, Hélio Elkis, Peter Falkai, Wolfgang Fleischhacker, Oliver Freudenreich, Ary Gadelha, Wolfgang Gäebel, Birte Glenthøj, Donald Goff, Ariel Graff‐Guerrero, Jorge Hallak, Alkomiet Hasan, William G. Honer, Philip Homan, Oliver Howes, René S. Kahn, Stefan Kaiser, John M. Kane, James L. Kennedy, Bruce J. Kinon, Euitae Kim, Stephen M. Lawrie, Jimmy Lee, Stefan Leucht, F. Markus Leweke, Jan Libiger, Antony Loebel, James H. MacCabe, Stephen R. Marder, Robert A. McCutcheon, Ingrid Melle, Herbert Y. Meltzer, Armida Mucci, Dieter Naber, Shinchiro Nakajima, Jimmi Nielsen, Oisín O’Brien, Akin Ojagbemi, Christos Pantelis, Joseph Peuskens, Steven G. Potkin, Tiago Reis Marques, Thomas J. Raedler, Gary Remington, Susan L. Rossell, Jose Rubio-Lorente, Gabriele Sachs, Dan Siskind, Cynthia Siu, Iris E. Sommer, Jun Soo Kwon, Takefumi Suzuki, Jaana Suvisaari, Hiroyoshi Takeuchi, Rajiv Tandon, David Taylor, Neil Thomas, Jari Tiihonen, Hiroyuki Uchida, Alp Üçok, Daniel Umbricht, Ganesan Venkatasubramanian, Elias Wagner, James Walters, Chuanyue Wang and 2 more - Schizophrenia Bulletin 2023 cited by 38

  10. Impact of primary negative symptoms on functional outcomes in schizophrenia

    Authors: Gagan Fervaha, George Foussias, Ofer Agid, Gary Remington - European Psychiatry 2014 cited by 205

  11. Pharmacological interventions for prevention of weight gain in people with schizophrenia

    Authors: Sri Mahavir Agarwal, Nicolette Stogios, Zohra Ahsan, Jonathan Lockwood, Markus J. Duncan, Hiroyoshi Takeuchi, Tony Cohn, Valerie H. Taylor, Gary Remington, Guy Faulkner, Margaret Hahn - Cochrane Database of Systematic Reviews 2022 cited by 48

  12. Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial

    Authors: Sri Mahavir Agarwal, Roshni Panda, Kenya A. Costa-Dookhan, Nicole E. MacKenzie, Quinn Casuccio Treen, Fernando Caravaggio, Eyesha Hashim, General Leung, Anish Kirpalani, Kelly Matheson, Araba Chintoh, Caroline K. Kramer, Aristotle N. Voineskos, Ariel Graff‐Guerrero, Gary Remington, Margaret Hahn - Translational Psychiatry 2021 cited by 39

  13. Negative Symptoms in Schizophrenia: Avolition and Occam's Razor

    Authors: George Foussias, Gary Remington - Schizophrenia Bulletin 2008 cited by 586

  14. Negative symptoms of schizophrenia: Clinical features, relevance to real world functioning and specificity versus other CNS disorders

    Authors: George Foussias, Ofer Agid, Gagan Fervaha, Gary Remington - European Neuropsychopharmacology 2013 cited by 248

  15. An Algorithm-Based Approach to First-Episode Schizophrenia

    Authors: Ofer Agid, Tamara Arenovich, Gautam Sajeev, Robert B. Zipursky, Shitij Kapur, George Foussias, Gary Remington - The Journal of Clinical Psychiatry 2011 cited by 223

  16. Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment

    Authors: Masataka Wada, Yoshihiro Noda, Yusuke Iwata, Sakiko Tsugawa, Kazunari Yoshida, Hideaki Tani, Yoji Hirano, Shinsuke Koike, Daiki Sasabayashi, Haruyuki Katayama, Eric Plitman, Kazutaka Ohi, Fumihiko Ueno, Fernando Caravaggio, Teruki Koizumi, Philip Gerretsen, Takefumi Suzuki, Hiroyuki Uchida, Daniel J. Müller, Masaru Mimura, Gary Remington, Anthony A. Grace, Ariel Graff‐Guerrero, Shinichiro Nakajima - Molecular Psychiatry 2022 cited by 115

  17. Canadian Treatment Guidelines for Individuals at Clinical High Risk of Psychosis

    Authors: Jean Addington, Donald Addington, Sabina Abidi, Thomas J. Raedler, Gary Remington - The Canadian Journal of Psychiatry 2017 cited by 82

  18. Increased Stress-Induced Dopamine Release in Psychosis

    Authors: Romina Mizrahi, Jean Addington, Pablo Rusjan, Ivonne Suridjan, Alvina Ng, Isabelle Boileau, Jens C. Pruessner, Gary Remington, Sylvain Houle, Alan A. Wilson - Biological Psychiatry 2012 cited by 274

  19. Treatment Recommendations for Tardive Dyskinesia

    Authors: Lucia Ricciardi, Tamara Pringsheim, Thomas R. E. Barnes, Davide Martino, David M. Gardner, Gary Remington, Donald Addington, Francesca Morgante, Norman Poole, Alan Carson, Mark J. Edwards - The Canadian Journal of Psychiatry 2019 cited by 100

  20. Adherence to Oral Antipsychotics Measured by Electronic Adherence Monitoring in Schizophrenia: A Systematic Review and Meta-analysis

    Authors: Hodaka Yaegashi, So Kirino, Gary Remington, Fuminari Misawa, Hiroyoshi Takeuchi - CNS Drugs 2020 cited by 95

  21. Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review

    Authors: Raghunath Singh, Nicolette Stogios, Emily R. Smith, Jiwon Lee, Kateryna Maksyutynsk, Emily Au, David C. Wright, Giada De Palma, Ariel Graff‐Guerrero, Philip Gerretsen, Daniel J. Müller, Gary Remington, Margaret Hahn, Sri Mahavir Agarwal - Therapeutic Advances in Psychopharmacology 2022 cited by 40

  22. Treating Negative Symptoms in Schizophrenia: an Update

    Authors: Gary Remington, George Foussias, Gagan Fervaha, Ofer Agid, Hiroyoshi Takeuchi, Jimmy Lee, Margaret Hahn - Current Treatment Options in Psychiatry 2016 cited by 172

  23. Motivational Deficits and Cognitive Test Performance in Schizophrenia

    Authors: Gagan Fervaha, Konstantine K. Zakzanis, George Foussias, Ariel Graff‐Guerrero, Ofer Agid, Gary Remington - JAMA Psychiatry 2014 cited by 155

  24. The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review

    Authors: Parita Shah, Yusuke Iwata, Eric Plitman, Eric E. Brown, Fernando Caravaggio, Julia Kim, Shinichiro Nakajima, Margaret Hahn, Gary Remington, Philip Gerretsen, Ariel Graff‐Guerrero - Psychiatry Research 2018 cited by 96